Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Abstract Background This study evaluated the cost-effectiveness of replacing standard intravenous therapy (taxane) with oral S-1 therapy for first-line metastatic breast cancer treatment. Methods This cost-effectiveness analysis was based on data from a randomized phase III trial (SELECT BC). As cos...

Full description

Bibliographic Details
Main Authors: Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Mitsuko Mouri, Yasuhiro Hagiwara, Takuya Kawahara, Shozo Ohsumi, Yasuo Hozumi, Yoshiaki Sagara, Yasuo Ohashi, Hirofumi Mukai
Format: Article
Language:English
Published: BMC 2017-11-01
Series:BMC Cancer
Subjects:
Cost-effectiveness analysis
Quality-adjusted life years
Breast neoplasms
Randomized controlled trial
S-1
Taxoids
Online Access:http://link.springer.com/article/10.1186/s12885-017-3774-7

Internet

http://link.springer.com/article/10.1186/s12885-017-3774-7

Similar Items